Recent metabolic studies have shown novel findings in asymptomatic FMR1 premutation carriers and FXTAS, which provide promising insight through identification of potential biomarkers and therapeutic pathways. This evidence concerns the gene FMR1 and fragile X-associated tremor/ataxia syndrome.